ET patients with CALR mutations accounted for 46.8% of patients who had non-mutated JAK2. Of the ET patients with CALR mutations, 13 (59.1%) had Type 1 mutation and 9 (40.9%) had Type 2 mutation. Here, JAK2 is linked to essential thrombocythemia.